Genetic variants in microRNA machinery genes are associated [corrected] with idiopathic recurrent pregnancy loss risk

Yong Wook Jung1, Young Joo Jeon2, HyungChul Rah2

  • 1Department of Obstetrics and Gynecology, CHA Gangnam Medical Center, CHA University, Seoul, South Korea.

Plos One
|April 29, 2014
PubMed
Abstract

Insights

Genetic variations in miRNA machinery genes like RAN and DROSHA/DICER are linked to recurrent pregnancy loss (RPL) risk in Korean women. These findings highlight potential genetic factors influencing reproductive health.

Area of Science:

  • Reproductive biology
  • Genetics
  • Molecular biology

Background:

  • MicroRNA (miRNA) biogenesis pathways, involving key molecules like DROSHA, XPO5, and DICER, are active in the human placenta.
  • miRNAs play crucial roles in regulating uterine gene expression during the peri-implantation period and in maintaining maternal-fetal immune tolerance.

Purpose of the Study:

  • To investigate the association between genetic polymorphisms in miRNA machinery genes and idiopathic recurrent pregnancy loss (RPL) in Korean women.

Main Methods:

  • A case-control study was conducted with 338 women experiencing RPL and 238 controls.
  • Genotyping of DICER, DROSHA, RAN GTPase (RAN), and exportin-5 (XPO5) gene polymorphisms was performed using PCR-RFLP.
  • Logistic regression analysis and multifactor dimensionality reduction (MDR) were used to assess associations and gene-gene interactions.

Main Results:

  • Specific genotypes of RAN (rs14035) and combined genotypes of DICER/DROSHA, DICER/RAN, and DICER/XPO5 were significantly associated with altered RPL risk.
  • Certain allele combinations (DICER/DROSHA/RAN/XPO5) were found to be significantly more frequent in the RPL group.

Conclusions:

  • The study establishes a relationship between RPL development and polymorphisms in the miRNA machinery gene RAN, as well as combined genotypes of DROSHA and DICER.
  • These findings suggest that genetic variations in miRNA biogenesis genes may contribute to the etiology of idiopathic RPL.

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
21.1K
MicroRNAs01:22

MicroRNAs

9.8K
piRNA - Piwi-interacting RNAs02:57

piRNA - Piwi-interacting RNAs

PIWI-interacting RNAs, or piRNAs, are the most abundant short non-coding RNAs. More than 20,000 genes have been found in humans that code for piRNAs while only 2000 genes have been found for miRNAs. piRNAs can act at the transcriptional and post-transcriptional levels and have a vital role in silencing transposable elements present in germ cells. They are also involved in epigenetic silencing and activation. Previously, they were thought to function only in germ cells but new evidence suggests...
6.1K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
159
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121